Overview
Spica Therapeutics leverages proprietary functional macrophage fingerprinting technology to identify and selectively target disease-relevant macrophage subsets. Founded on research from the University of Aarhus, Southern Denmark University, and INSERM, the company is advancing two lead programs in oncology and fibroinflammatory diseases.
Funding & milestones
1 events found for Spica Therapeutics · 2025
SeedVenture / equityDetailsEUR 10M
Reported amount EUR 10,000,000
Source not attached to this recordDeal record
Recorded history so far. Original currencies are preserved; amounts in different currencies are not added together. Debt, grants, acquisitions and listings are separate event types. Undated events appear last.
Backers
QBIC
Belgian inter-university deep-tech fund backed by UGent, VUB, UAntwerp, UHasselt, ULiege, VITO, imec, and partner hospitals.
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.